GlassScriptPhysician profile
Alan Roger Shuster
NPI 1639266034
$12,294.24
in general payments reported to CMS, 2019-2025
35 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,167 · 2020: $378 · 2021: $2,003 · 2022: $1,450 · 2023: $2,886 · 2024: $1,679 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,297.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,642.54 | 2019-2025 | Clareon, Argos, Clareon Panoptix Pro |
| Lensar, INC. | $853.03 | 2023-2024 | Lensar Laser System |
| Sight Sciences, INC. | $810.87 | 2019-2024 | Omni Surgical System |
| Horizon Therapeutics Plc | $807.35 | 2021-2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $578.00 | 2019-2025 | Tecnis Iol, Tecnis Iol, Catalys System |
| Bausch & Lomb Americas INC. | $573.18 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Harrow Eye, LLC | $564.06 | 2024-2025 | Iheezo, Vevye, Triesence |
| Kala Pharmaceuticals, INC. | $537.48 | 2019-2021 | |
| Dutch Ophthalmic, USA | $463.47 | 2023 | Eva, Combined Machine, Tissueblue |
| Rayner Intraocular Lenses Limited | $437.88 | 2022-2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $407.76 | 2019-2021 | |
| Allergan, INC. | $402.87 | 2019-2022 | |
| Genentech USA, INC. | $393.94 | 2022-2025 | Susvimo, Vabysmo |
| Carl Zeiss Meditec USA, INC. | $363.23 | 2023-2025 | Quatera 700, Clarus |
| Aerie Pharmaceuticals, INC. | $358.86 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $341.61 | 2021-2023 | Flarex |
| Omeros Corporation | $336.36 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $334.23 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $324.54 | 2021-2024 | Acthar |
| Novartis Pharmaceuticals Corporation | $272.82 | 2019-2023 | |
| Abbvie INC. | $209.64 | 2022-2024 | Alphagan P, Vuity, Lumigan |
| Oyster Point Pharma, INC. | $204.58 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $198.06 | 2024-2025 | Xdemvy |
| Hoffmann-La Roche Limited | $140.40 | 2019 | |
| New World Medical,INC. | $135.29 | 2025 | Streamline, Via360, Clearpath |
| Ani Pharmaceuticals, INC. | $120.65 | 2024 | Purified Cortrophin Gel |
| Spark Therapeutics, INC. | $105.68 | 2019 | |
| Eyepoint US, INC. | $101.26 | 2019-2021 | |
| Dompe US, INC. | $66.71 | 2024-2025 | Oxervate |
| Shire North American Group INC | $63.60 | 2019 | |
| Ocular Therapeutix, INC. | $55.16 | 2021-2022 | |
| Astellas Pharma US INC | $27.71 | 2025 | Izervay |
| Rxsight INC | $23.41 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Amgen INC. | $18.61 | 2025 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Shuster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.